EA201892368A1 - ИНГИБИТОРЫ ErbB И ИХ ПРИМЕНЕНИЕ - Google Patents

ИНГИБИТОРЫ ErbB И ИХ ПРИМЕНЕНИЕ

Info

Publication number
EA201892368A1
EA201892368A1 EA201892368A EA201892368A EA201892368A1 EA 201892368 A1 EA201892368 A1 EA 201892368A1 EA 201892368 A EA201892368 A EA 201892368A EA 201892368 A EA201892368 A EA 201892368A EA 201892368 A1 EA201892368 A1 EA 201892368A1
Authority
EA
Eurasian Patent Office
Prior art keywords
application
erbb inhibitors
erbb
inhibitors
describes
Prior art date
Application number
EA201892368A
Other languages
English (en)
Inventor
Кристофер Новотни
Кеван М. Шокат
Вэйцзюнь Шэнь
Original Assignee
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа
Дзе Скриппс Рисерч Инститьют
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа, Дзе Скриппс Рисерч Инститьют filed Critical Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа
Publication of EA201892368A1 publication Critical patent/EA201892368A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Epoxy Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Drilling Tools (AREA)
  • Developing Agents For Electrophotography (AREA)

Abstract

В настоящем документе, inter alia, описаны композиции модуляторов ErbB и способы их применения.
EA201892368A 2016-04-19 2017-04-19 ИНГИБИТОРЫ ErbB И ИХ ПРИМЕНЕНИЕ EA201892368A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662324864P 2016-04-19 2016-04-19
PCT/US2017/028437 WO2017184775A1 (en) 2016-04-19 2017-04-19 Erbb inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
EA201892368A1 true EA201892368A1 (ru) 2019-05-31

Family

ID=60116344

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892368A EA201892368A1 (ru) 2016-04-19 2017-04-19 ИНГИБИТОРЫ ErbB И ИХ ПРИМЕНЕНИЕ

Country Status (13)

Country Link
US (1) US20190119284A1 (ru)
EP (1) EP3445768A4 (ru)
JP (1) JP2019514869A (ru)
CN (1) CN109952306A (ru)
AU (1) AU2017253096A1 (ru)
BR (1) BR112018071592A8 (ru)
CA (1) CA3021324A1 (ru)
EA (1) EA201892368A1 (ru)
IL (1) IL262400A (ru)
MX (1) MX2018012797A (ru)
PH (1) PH12018502233A1 (ru)
SG (1) SG11201809223PA (ru)
WO (1) WO2017184775A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111032082A (zh) * 2017-04-28 2020-04-17 西雅图基因公司 Her2阳性癌症的治疗
US20210347785A1 (en) * 2018-08-01 2021-11-11 Shanghai Ennovabio Pharmaceuticals Co., Ltd. Preparation and application of aromatic compound having immunoregulatory function
AU2020206640B2 (en) * 2019-01-11 2022-09-08 Taiho Pharmaceutical Co., Ltd. Pyrimidine compound or salt thereof
WO2021127397A1 (en) * 2019-12-19 2021-06-24 Black Diamond Therapeutics, Inc. Nitrogen heterocyclic compounds and methods of use
CN111303158A (zh) * 2020-04-09 2020-06-19 成都睿智化学研究有限公司 一种（4-氯-1H-吡唑啉[3,4-d]嘧啶-3-基）芳基甲酮的制备方法
TW202216151A (zh) * 2020-07-15 2022-05-01 日商大鵬藥品工業股份有限公司 含有使用於腫瘤之治療之嘧啶化合物之組合

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726302A (en) * 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
US5646128A (en) * 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
AU665184B2 (en) * 1991-01-23 1995-12-21 Gensia, Inc. Adenosine kinase inhibitors
AU711592B2 (en) * 1995-04-03 1999-10-14 Novartis Ag Pyrazole derivatives and processes for the preparation thereof
GB0119249D0 (en) * 2001-08-07 2001-10-03 Novartis Ag Organic compounds
JP4881875B2 (ja) * 2004-12-14 2012-02-22 アストラゼネカ アクチボラグ 抗腫瘍剤としてのピラゾロピリミジン化合物
JP2010523712A (ja) * 2007-04-13 2010-07-15 スーパージェン， インコーポレイテッド 癌または過剰増殖の治療に有用なａｘｌキナーゼ阻害剤
KR101705158B1 (ko) * 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
TW201107328A (en) * 2009-07-28 2011-03-01 Daiichi Sankyo Co Ltd Pyrrolo [2,3-d] pyrimidine derivatives
WO2011149827A1 (en) * 2010-05-24 2011-12-01 Glaxosmithkline Llc Compounds and methods
CN103570723B (zh) * 2012-07-27 2016-07-13 广西梧州制药（集团）股份有限公司 吡唑并嘧啶衍生物及其制备方法和在药物制备中的用途

Also Published As

Publication number Publication date
IL262400A (en) 2018-12-31
BR112018071592A8 (pt) 2019-02-26
MX2018012797A (es) 2020-01-09
CA3021324A1 (en) 2017-10-26
WO2017184775A1 (en) 2017-10-26
PH12018502233A1 (en) 2019-06-03
US20190119284A1 (en) 2019-04-25
BR112018071592A2 (pt) 2019-02-12
EP3445768A4 (en) 2019-12-18
EP3445768A1 (en) 2019-02-27
SG11201809223PA (en) 2018-11-29
JP2019514869A (ja) 2019-06-06
CN109952306A (zh) 2019-06-28
AU2017253096A1 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
CL2019000424A1 (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
EA201890493A1 (ru) РЕПРЕССОРЫ Htt И ИХ ПРИМЕНЕНИЕ
EA201890749A1 (ru) ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) И ИХ ПРИМЕНЕНИЕ
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
EA201992497A1 (ru) МОДУЛЯТОРЫ K-Ras
BR112019012342A2 (pt) anticorpos il-11
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA202092435A3 (ru) Моноклональные антитела против bcma
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
BR112019012343A2 (pt) anticorpos il-11ra
EA201792443A1 (ru) МОДУЛЯТОРЫ K-Ras
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
EA201892368A1 (ru) ИНГИБИТОРЫ ErbB И ИХ ПРИМЕНЕНИЕ
CL2019001554S1 (es) Automóvil.
EA201691974A1 (ru) Антитела против ox40 и способы их применения
EA201790173A1 (ru) Антитела, связывающие axl
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
EA201992232A1 (ru) Композиции и способы для иммуноонкологии
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
EA201791992A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
EA201792000A1 (ru) Ингибиторы грелин-o-ацилтрансферазы